Agreements reached under this partnership
Business alliances- 1
Entered into a legally binding term sheet for a U.S. sales partnership.
- 2
Finalizing the detailed terms of the sales license agreement.
- 3
Review of the sales strategy, supply plan and agreement terms.
- 4
Discussions regarding the scope of responsibilities and cost sharing associated with increasing production capacity, among other matters.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
Sales volume expected over the next several years is projected to exceed the assumptions made when the term sheet was signed
The impact on the Company's results for the fiscal year ending December 2026 is expected to be minor
| Item | Details |
|---|---|
| Name of alliance partner | Terrain Pharmaceuticals |
| Alliance partner's business activities | A U.S. specialty pharmaceutical company with more than 10 years of experience in the development and sale of topical analgesics, which has brought prescription and over-the-counter topical patches and semi-solid formulations, including lidocaine- and NSAID-based products, to market. |
| Alliance partner's location | Reno, Nevada, U.S. |
| Type of alliance | Business alliances |
| Details of the alliance | Entered into a legally binding term sheet for a U.S. sales partnership., Finalizing the detailed terms of the sales license agreement., Review of the sales strategy, supply plan and agreement terms., Discussions regarding the scope of responsibilities and cost sharing associated with increasing production capacity, among other matters. |
| Numerical targets under the alliance | Sales volume expected over the next several years is projected to exceed the assumptions made when the term sheet was signed |
| Contract Date | May 2026 (legally binding term sheet) |
| Alliance start date | Sales launch is scheduled for sometime in 2026. |
| Impact on Business Performance | The impact on the Company's results for the fiscal year ending December 2026 is expected to be minor |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Time is being spent on discussions to reflect specific terms in the agreement, including the scope of responsibilities and cost sharing associated with increasing production capacity in anticipation of higher sales volumes. Another reason cited is that sales volumes expected over the next several years are now projected to exceed the assumptions made when the term sheet was signed.